(Q46815372)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185470%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

Clinical and molecular predictors of response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185470%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185470%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Thibault de La Motte Rouge

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185470%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Alexander Valent

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185470%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Philippe Vielh

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185470%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Ludovic Lacroix

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185470%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

language of work or name

French

0 references

publication date

1 October 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185470%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

published in

Annales de Pathologie

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185470%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185470%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185470%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

353-363

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185470%20AND%20SRC:MED&resulttype=core&format=json

Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Epidermal growth factor receptor mutations in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

A simple and sensitive method for detecting major mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene in non-small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung.

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

Rapid detection of epidermal growth factor receptor mutations in non-small cell lung cancer using real-time polymerase chain reaction with TaqMan-MGB probes

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

In vivo elimination of acentric double minutes containing amplified MYCN from neuroblastoma tumor cells through the formation of micronuclei

1 reference

https://api.crossref.org/works/10.1016%2FS0242-6498%2807%2978274-3

7 January 2021

10.1016/S0242-6498(07)78274-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185470%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference